Hi all,We are pleased to announce this morning that we have...

Hi all,

We are pleased to announce this morning that we have received Human Research Ethics Committee (HREC) approval of our Phase I study for our MagSense technology. This approval enables us to finalise our contracts with individual study sites in Australia. As we have previously advised, the study remains on track to commence this calendar quarter.

We are also pleased to report manufacturing of our HER2 nanoparticle formulation continues on schedule, and we expect to complete the final step of GMP-compliant packaging of the material in time for the start of the study.

For more information, please refer to today’s ASX announcement here.

Once again we thank you for your support of Imagion Biosystems.